Mk-677 Half Life
MK-677 Half Life: What the Research Reports
Published by Peptara Labs · Updated · How we research and check our pages
The short answer
The MK-677 half life question is really a question about duration of action. MK-677 (ibutamoren) is long-acting: in published human trials it was taken by mouth, and growth hormone (GH) and IGF-1 stayed raised across the day (Chapman et al., JCEM 1996; Nass et al., Ann Intern Med 2008). A single precise plasma half-life value is not well established in the openly accessible peer-reviewed literature, so this page reports the documented duration of action rather than attaching a hard "X hours" number to a source it cannot verify.
This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
What is the half life of MK-677?
MK-677 half life is best understood as its duration of action: it stays active for a long time after an oral intake, though a precise, well-published plasma constant is hard to pin to a verifiable source.
Here is the honest picture. Two human studies gave MK-677 by mouth and reported a sustained rise in GH and IGF-1: a 1996 dose-ranging study in healthy elderly subjects (Chapman et al., JCEM 1996; doi:10.1210/jcem.81.12.8954023) and a 2-year trial in healthy older adults (Nass et al., Ann Intern Med 2008; doi:10.7326/0003-4819-149-9-200811040-00003). That sustained response is the strongest public evidence that MK-677 acts for roughly a full day. Detailed human plasma pharmacokinetic values in the openly accessible peer-reviewed literature are limited, and the specific "about 24 hours" figure repeated on vendor pages is not tied to a primary source we could verify. So this page will not attach a hard "X hours" number to a source it cannot stand behind. What is documented is the practical result: the hormone response stayed up across the day (Chapman et al., 1996; Nass et al., 2008).
If you only want the takeaway: MK-677 is long-acting, and and the published research reports a sustained GH and IGF-1 response after oral intake.
Why does MK-677 work by mouth for so long?
Because, in the trials that studied it, GH and IGF-1 stayed raised across roughly a full day after oral intake.
MK-677 is one of the few GH-pathway compounds that works taken by mouth. Most GH secretagogues are injected. In the 1996 dose-ranging study, the top oral arm raised the mean 24-hour GH concentration by about 97% and nearly doubled IGF-1 over 4 weeks (Chapman et al., 1996). In the later 2-year study, oral MK-677 produced a roughly 1.8-fold rise in 24-hour mean GH and a 1.5-fold rise in IGF-1 at 12 months, with no injections (Nass et al., 2008). That combination, oral route plus long duration, is the reason it draws interest in research settings.
What is the difference between half life and duration of action for MK-677?
Half life is how long it takes blood levels of the compound to fall by half, while duration of action is how long the downstream GH and IGF-1 response lasts, and for MK-677 the second one is what the trials actually measured.
The two often get merged into a single "24-hour" claim, but they are not the same thing. IGF-1 is a slow-moving, integrated marker: it reflects average GH activity over time rather than moment-to-moment pulses. So even after the compound itself starts to clear, IGF-1 can stay raised. That is why a duration-of-effect number tends to look longer than a strict plasma clearance number, and why people round MK-677 to "about a day."
How does MK-677's duration compare to injectable GH secretagogues?
MK-677 is oral and long-acting, sitting closer to long-acting CJC-1295 with DAC than to a short pulse agent like ipamorelin.
The ranges below reflect what published studies report. This is educational, not a prescription or a personal recommendation.
| Compound | Route | Action profile studied | GH / IGF-1 pattern reported | Source |
|---|---|---|---|---|
| MK-677 (ibutamoren) | Oral | Long-acting, oral | Sustained rise held over 2 years of the trial | Nass et al., 2008 |
| Ipamorelin | Injectable | Short-acting pulse | Selective GH release, minimal cortisol or prolactin change | Raun et al., 1998 |
| CJC-1295 with DAC | Injectable | Long-acting | GH up 2 to 10 fold for 6+ days; IGF-1 up 1.5 to 3 fold for 9 to 11 days; estimated half-life 5.8 to 8.1 days | Teichman et al., 2006 |
The pattern is the point. A short-acting pulse agent produces a sharper, briefer, selective GH release (Raun et al., 1998). A long-acting design keeps levels up for a week or more after one injection (Teichman et al., 2006). MK-677 lands in the sustained camp, delivered orally (Nass et al., 2008).
Does a longer half life mean MK-677 is safer or better?
No. A longer duration of action also means the side effects last, and in a 2-year trial MK-677 raised fasting glucose and lowered insulin sensitivity (Nass et al., 2008).
Sustained signaling cuts both ways. The steady hormone response is what makes MK-677 long-acting, but the same steady exposure sustained the metabolic changes seen in the 2-year study: fasting blood glucose rose by about 0.3 mmol/L and insulin sensitivity by the QUICKI index fell over 12 months (Nass et al., 2008). "Long-acting" describes how the compound behaves, not whether it is right for any one person. Those are separate questions, and the second belongs with a qualified clinician.
What did the human research report for duration?
In the 2-year trial, participants took oral MK-677 or placebo, and GH and IGF-1 stayed raised for the duration (Nass et al., 2008).
The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.
| Detail | What the trial reported | Source |
|---|---|---|
| Compound | Oral MK-677 (ibutamoren) | Nass et al., 2008 |
| Duration | Up to 2 years (year-1 primary analysis) | Nass et al., 2008 |
| Population | 65 healthy adults, ages 60 to 81 | Nass et al., 2008 |
| GH / IGF-1 | 24-hour mean GH up about 1.8-fold; IGF-1 up about 1.5-fold at 12 months | Nass et al., 2008 |
| Body composition | Fat-free mass rose about 1.1 kg vs a fall on placebo | Nass et al., 2008 |
| Metabolic finding | Fasting glucose up about 0.3 mmol/L; insulin sensitivity (QUICKI) fell | Nass et al., 2008 |
This is research-reported information, not a recommendation. It describes what one published trial measured. Any personal decision about MK-677 should be made with a qualified clinician who can weigh the metabolic findings above.
Keep reading
Related research and verification
Mk-677 Half Life: FAQ
What is the half life of MK-677 in hours?
The honest answer is that MK-677 is long-acting, but a single precise plasma half-life value is not well established in the openly accessible peer-reviewed literature. What is documented is that oral MK-677 kept GH and IGF-1 raised across the day in human trials (Chapman et al., 1996; Nass et al., 2008).
Why do people say MK-677 has a 24-hour half life?
Because IGF-1 stays raised for roughly a day in the trials, people round the duration of action to "24 hours" and call it half-life. Strictly, that figure describes how long the hormone response lasts, not how fast the molecule clears the blood, and the exact "24 hours" number is not tied to a primary source we could verify.
Is MK-677 a peptide?
Chemically, MK-677 is a small-molecule (non-peptide) growth hormone secretagogue taken by mouth, not a true peptide (Chapman et al., 1996). It is often grouped with research peptides because it works on the same GH and IGF-1 pathway.
Does MK-677's long duration cause side effects?
In one 2-year trial, the same sustained action also sustained metabolic changes: MK-677 raised fasting glucose by about 0.3 mmol/L and lowered insulin sensitivity (Nass et al., 2008).
How was MK-677 given in human research?
By mouth, in a 4-week dose-ranging study and in a placebo-controlled trial lasting up to two years (Chapman et al., 1996; Nass et al., 2008). This page does not print the amounts; any personal decision belongs with a qualified clinician.
Is MK-677 an approved medicine?
MK-677 has been studied in humans (Chapman et al., 1996; Nass et al., 2008) but is not an approved medicine. Peptara Labs offers it for research use only, not as a treatment.
References
- Chapman IM, Bach MA, Van Cauter E, et al. "Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects." Journal of Clinical Endocrinology & Metabolism. 1996;81(12):4249-4257. doi:10.1210/jcem.81.12.8954023. PMID 8954023.
- Nass R, Pezzoli SS, Oliveri MC, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial." Annals of Internal Medicine. 2008;149(9):601-611. doi:10.7326/0003-4819-149-9-200811040-00003. PMID 18981485. PMC2757071.
- Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID 9849822.
- Teichman SL, Neale A, Lawrence B, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PMID 16352683.
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.